Compared to HPV-negative tumors, HPV-positive tumors are genetically different and inversely correlated with biomarkers for poor prognosis (e.g., p53 mutations) [10,11], which determines the molecular profile of tumors and thus the tumor-associated process (e.g., infiltrates of immune cells [12]) These might explain the higher rates of response to radiation therapy and chemotherapy and better in HPV-positive tumors. The gene discussed is TP53; the disease is neoplasm.